Theranova Randomized, Controlled, Trial (RCT) in China
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 323 participants.
Also called NCT05309291
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 323 participants
- Registry
-
NCT05309291
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05309291. Randomized; no masking; primary purpose treatment. Start 2022-06-22 (actual); primary completion 2023-07-06 (actual). Results posted on 2024-10-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Theranova Randomized, Controlled, Trial (RCT) in China
- Acronym
- ROCKet
- Condition
- Chronic Kidney Failure
- Condition
- Acute Kidney Failure
- Intervention (Device)
- Theranova 400 Dialyzer
- Intervention (Device)
- FX 800 Dialyzer
- Lead sponsor
- Vantive Health LLC
- Collaborator
- Baxter Healthcare Corporation
Record details
- Record id
cardio:ct-nct05309291- Content hash
966b2ada07b16293b6254d1b2d88a346f32532ada4e448be94ece7aea37f780e